Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue$207.71M$207.71M+38.6% vs Q1 2025 Net Income-$2.29M-$2.29MN/M vs Q1 2025 EPS Diluted-$0.04-$0.04N/M vs Q1 2025 Operating Income-$8,332,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$66,524,000+119.8% Margins · derivedOperating margin-4.0%+2.8 pt vs Q1 2025
Net margin-1.1%+6.8 pt vs Q1 2025
ended Mar 31, 2026 · filed May 5, 2026 · 35 d after period end